1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Migraine Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1.2.2 Specific Anti-migraine Drugs 1.2.3 Acute Therapies 1.2.4 Preventative Therapies 1.2.5 Other 1.3 Market by Application 1.3.1 Global Migraine Therapeutics Market Share by Application: 2017 VS 2021 VS 2028 1.3.2 Hospitals 1.3.3 Clinics 1.3.4 Household Use 1.3.5 Others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Migraine Therapeutics Market Perspective (2017-2028) 2.2 Migraine Therapeutics Growth Trends by Region 2.2.1 Migraine Therapeutics Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Migraine Therapeutics Historic Market Size by Region (2017-2022) 2.2.3 Migraine Therapeutics Forecasted Market Size by Region (2023-2028) 2.3 Migraine Therapeutics Market Dynamics 2.3.1 Migraine Therapeutics Industry Trends 2.3.2 Migraine Therapeutics Market Drivers 2.3.3 Migraine Therapeutics Market Challenges 2.3.4 Migraine Therapeutics Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Migraine Therapeutics Players by Revenue 3.1.1 Global Top Migraine Therapeutics Players by Revenue (2017-2022) 3.1.2 Global Migraine Therapeutics Revenue Market Share by Players (2017-2022) 3.2 Global Migraine Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Migraine Therapeutics Revenue 3.4 Global Migraine Therapeutics Market Concentration Ratio 3.4.1 Global Migraine Therapeutics Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Migraine Therapeutics Revenue in 2021 3.5 Migraine Therapeutics Key Players Head office and Area Served 3.6 Key Players Migraine Therapeutics Product Solution and Service 3.7 Date of Enter into Migraine Therapeutics Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Migraine Therapeutics Breakdown Data by Type 4.1 Global Migraine Therapeutics Historic Market Size by Type (2017-2022) 4.2 Global Migraine Therapeutics Forecasted Market Size by Type (2023-2028) 5 Migraine Therapeutics Breakdown Data by Application 5.1 Global Migraine Therapeutics Historic Market Size by Application (2017-2022) 5.2 Global Migraine Therapeutics Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Migraine Therapeutics Market Size (2017-2028) 6.2 North America Migraine Therapeutics Market Size by Country (2017-2022) 6.3 North America Migraine Therapeutics Market Size by Country (2023-2028) 6.4 United States 6.5 Canada 7 Europe 7.1 Europe Migraine Therapeutics Market Size (2017-2028) 7.2 Europe Migraine Therapeutics Market Size by Country (2017-2022) 7.3 Europe Migraine Therapeutics Market Size by Country (2023-2028) 7.4 Germany 7.5 France 7.6 U.K. 7.7 Italy 7.8 Russia 7.9 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Migraine Therapeutics Market Size (2017-2028) 8.2 Asia-Pacific Migraine Therapeutics Market Size by Country (2017-2022) 8.3 Asia-Pacific Migraine Therapeutics Market Size by Country (2023-2028) 8.4 China 8.5 Japan 8.6 South Korea 8.7 Southeast Asia 8.8 India 8.9 Australia 9 Latin America 9.1 Latin America Migraine Therapeutics Market Size (2017-2028) 9.2 Latin America Migraine Therapeutics Market Size by Country (2017-2022) 9.3 Latin America Migraine Therapeutics Market Size by Country (2023-2028) 9.4 Mexico 9.5 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Migraine Therapeutics Market Size (2017-2028) 10.2 Middle East & Africa Migraine Therapeutics Market Size by Country (2017-2022) 10.3 Middle East & Africa Migraine Therapeutics Market Size by Country (2023-2028) 10.4 Turkey 10.5 Saudi Arabia 10.6 UAE 11 Key Players Profiles 11.1 Allergan 11.1.1 Allergan Company Detail 11.1.2 Allergan Business Overview 11.1.3 Allergan Migraine Therapeutics Introduction 11.1.4 Allergan Revenue in Migraine Therapeutics Business (2017-2022) 11.1.5 Allergan Recent Development 11.2 Merck 11.2.1 Merck Company Detail 11.2.2 Merck Business Overview 11.2.3 Merck Migraine Therapeutics Introduction 11.2.4 Merck Revenue in Migraine Therapeutics Business (2017-2022) 11.2.5 Merck Recent Development 11.3 Pfizer 11.3.1 Pfizer Company Detail 11.3.2 Pfizer Business Overview 11.3.3 Pfizer Migraine Therapeutics Introduction 11.3.4 Pfizer Revenue in Migraine Therapeutics Business (2017-2022) 11.3.5 Pfizer Recent Development 11.4 Teva 11.4.1 Teva Company Detail 11.4.2 Teva Business Overview 11.4.3 Teva Migraine Therapeutics Introduction 11.4.4 Teva Revenue in Migraine Therapeutics Business (2017-2022) 11.4.5 Teva Recent Development 11.5 Amgen 11.5.1 Amgen Company Detail 11.5.2 Amgen Business Overview 11.5.3 Amgen Migraine Therapeutics Introduction 11.5.4 Amgen Revenue in Migraine Therapeutics Business (2017-2022) 11.5.5 Amgen Recent Development 11.6 Johnson & Johnson 11.6.1 Johnson & Johnson Company Detail 11.6.2 Johnson & Johnson Business Overview 11.6.3 Johnson & Johnson Migraine Therapeutics Introduction 11.6.4 Johnson & Johnson Revenue in Migraine Therapeutics Business (2017-2022) 11.6.5 Johnson & Johnson Recent Development 11.7 Endo International 11.7.1 Endo International Company Detail 11.7.2 Endo International Business Overview 11.7.3 Endo International Migraine Therapeutics Introduction 11.7.4 Endo International Revenue in Migraine Therapeutics Business (2017-2022) 11.7.5 Endo International Recent Development 11.8 GlaxoSmithKline 11.8.1 GlaxoSmithKline Company Detail 11.8.2 GlaxoSmithKline Business Overview 11.8.3 GlaxoSmithKline Migraine Therapeutics Introduction 11.8.4 GlaxoSmithKline Revenue in Migraine Therapeutics Business (2017-2022) 11.8.5 GlaxoSmithKline Recent Development 11.9 Impax 11.9.1 Impax Company Detail 11.9.2 Impax Business Overview 11.9.3 Impax Migraine Therapeutics Introduction 11.9.4 Impax Revenue in Migraine Therapeutics Business (2017-2022) 11.9.5 Impax Recent Development 11.10 Abbott 11.10.1 Abbott Company Detail 11.10.2 Abbott Business Overview 11.10.3 Abbott Migraine Therapeutics Introduction 11.10.4 Abbott Revenue in Migraine Therapeutics Business (2017-2022) 11.10.5 Abbott Recent Development 11.11 Bayer 11.11.1 Bayer Company Detail 11.11.2 Bayer Business Overview 11.11.3 Bayer Migraine Therapeutics Introduction 11.11.4 Bayer Revenue in Migraine Therapeutics Business (2017-2022) 11.11.5 Bayer Recent Development 11.12 Eli Lilly 11.12.1 Eli Lilly Company Detail 11.12.2 Eli Lilly Business Overview 11.12.3 Eli Lilly Migraine Therapeutics Introduction 11.12.4 Eli Lilly Revenue in Migraine Therapeutics Business (2017-2022) 11.12.5 Eli Lilly Recent Development 11.13 Novartis International 11.13.1 Novartis International Company Detail 11.13.2 Novartis International Business Overview 11.13.3 Novartis International Migraine Therapeutics Introduction 11.13.4 Novartis International Revenue in Migraine Therapeutics Business (2017-2022) 11.13.5 Novartis International Recent Development 11.14 Ethypharm 11.14.1 Ethypharm Company Detail 11.14.2 Ethypharm Business Overview 11.14.3 Ethypharm Migraine Therapeutics Introduction 11.14.4 Ethypharm Revenue in Migraine Therapeutics Business (2017-2022) 11.14.5 Ethypharm Recent Development 11.15 Kowa Pharmaceuticals America 11.15.1 Kowa Pharmaceuticals America Company Detail 11.15.2 Kowa Pharmaceuticals America Business Overview 11.15.3 Kowa Pharmaceuticals America Migraine Therapeutics Introduction 11.15.4 Kowa Pharmaceuticals America Revenue in Migraine Therapeutics Business (2017-2022) 11.15.5 Kowa Pharmaceuticals America Recent Development 11.16 Winston Pharmaceuticals 11.16.1 Winston Pharmaceuticals Company Detail 11.16.2 Winston Pharmaceuticals Business Overview 11.16.3 Winston Pharmaceuticals Migraine Therapeutics Introduction 11.16.4 Winston Pharmaceuticals Revenue in Migraine Therapeutics Business (2017-2022) 11.16.5 Winston Pharmaceuticals Recent Development 11.17 AstraZeneca 11.17.1 AstraZeneca Company Detail 11.17.2 AstraZeneca Business Overview 11.17.3 AstraZeneca Migraine Therapeutics Introduction 11.17.4 AstraZeneca Revenue in Migraine Therapeutics Business (2017-2022) 11.17.5 AstraZeneca Recent Development 11.18 Amirall 11.18.1 Amirall Company Detail 11.18.2 Amirall Business Overview 11.18.3 Amirall Migraine Therapeutics Introduction 11.18.4 Amirall Revenue in Migraine Therapeutics Business (2017-2022) 11.18.5 Amirall Recent Development 11.19 OptiNose 11.19.1 OptiNose Company Detail 11.19.2 OptiNose Business Overview 11.19.3 OptiNose Migraine Therapeutics Introduction 11.19.4 OptiNose Revenue in Migraine Therapeutics Business (2017-2022) 11.19.5 OptiNose Recent Development 11.20 Revance Therapeutics 11.20.1 Revance Therapeutics Company Detail 11.20.2 Revance Therapeutics Business Overview 11.20.3 Revance Therapeutics Migraine Therapeutics Introduction 11.20.4 Revance Therapeutics Revenue in Migraine Therapeutics Business (2017-2022) 11.20.5 Revance Therapeutics Recent Development 11.21 RedHill Biopharma 11.21.1 RedHill Biopharma Company Detail 11.21.2 RedHill Biopharma Business Overview 11.21.3 RedHill Biopharma Migraine Therapeutics Introduction 11.21.4 RedHill Biopharma Revenue in Migraine Therapeutics Business (2017-2022) 11.21.5 RedHill Biopharma Recent Development 11.22 Bausch Health 11.22.1 Bausch Health Company Detail 11.22.2 Bausch Health Business Overview 11.22.3 Bausch Health Migraine Therapeutics Introduction 11.22.4 Bausch Health Revenue in Migraine Therapeutics Business (2017-2022) 11.22.5 Bausch Health Recent Development 11.23 NeurAxon 11.23.1 NeurAxon Company Detail 11.23.2 NeurAxon Business Overview 11.23.3 NeurAxon Migraine Therapeutics Introduction 11.23.4 NeurAxon Revenue in Migraine Therapeutics Business (2017-2022) 11.23.5 NeurAxon Recent Development 11.24 Biohaven Pharma 11.24.1 Biohaven Pharma Company Detail 11.24.2 Biohaven Pharma Business Overview 11.24.3 Biohaven Pharma Migraine Therapeutics Introduction 11.24.4 Biohaven Pharma Revenue in Migraine Therapeutics Business (2017-2022) 11.24.5 Biohaven Pharma Recent Development 11.25 Eisai 11.25.1 Eisai Company Detail 11.25.2 Eisai Business Overview 11.25.3 Eisai Migraine Therapeutics Introduction 11.25.4 Eisai Revenue in Migraine Therapeutics Business (2017-2022) 11.25.5 Eisai Recent Development 11.26 Valeant Pharma 11.26.1 Valeant Pharma Company Detail 11.26.2 Valeant Pharma Business Overview 11.26.3 Valeant Pharma Migraine Therapeutics Introduction 11.26.4 Valeant Pharma Revenue in Migraine Therapeutics Business (2017-2022) 11.26.5 Valeant Pharma Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Migraine Therapeutics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028 Table 2. Key Players of Specific Anti-migraine Drugs Table 3. Key Players of Acute Therapies Table 4. Key Players of Preventative Therapies Table 5. Key Players of Other Table 6. Global Migraine Therapeutics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028 Table 7. Global Migraine Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 8. Global Migraine Therapeutics Market Size by Region (2017-2022) & (US$ Million) Table 9. Global Migraine Therapeutics Market Share by Region (2017-2022) Table 10. Global Migraine Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 11. Global Migraine Therapeutics Market Share by Region (2023-2028) Table 12. Migraine Therapeutics Market Trends Table 13. Migraine Therapeutics Market Drivers Table 14. Migraine Therapeutics Market Challenges Table 15. Migraine Therapeutics Market Restraints Table 16. Global Migraine Therapeutics Revenue by Players (2017-2022) & (US$ Million) Table 17. Global Migraine Therapeutics Market Share by Players (2017-2022) Table 18. Global Top Migraine Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Migraine Therapeutics as of 2021) Table 19. Ranking of Global Top Migraine Therapeutics Companies by Revenue (US$ Million) in 2021 Table 20. Global 5 Largest Players Market Share by Migraine Therapeutics Revenue (CR5 and HHI) & (2017-2022) Table 21. Key Players Headquarters and Area Served Table 22. Key Players Migraine Therapeutics Product Solution and Service Table 23. Date of Enter into Migraine Therapeutics Market Table 24. Mergers & Acquisitions, Expansion Plans Table 25. Global Migraine Therapeutics Market Size by Type (2017-2022) & (US$ Million) Table 26. Global Migraine Therapeutics Revenue Market Share by Type (2017-2022) Table 27. Global Migraine Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 28. Global Migraine Therapeutics Revenue Market Share by Type (2023-2028) Table 29. Global Migraine Therapeutics Market Size by Application (2017-2022) & (US$ Million) Table 30. Global Migraine Therapeutics Revenue Market Share by Application (2017-2022) Table 31. Global Migraine Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 32. Global Migraine Therapeutics Revenue Market Share by Application (2023-2028) Table 33. North America Migraine Therapeutics Market Size by Country (2017-2022) & (US$ Million) Table 34. North America Migraine Therapeutics Market Size by Country (2023-2028) & (US$ Million) Table 35. Europe Migraine Therapeutics Market Size by Country (2017-2022) & (US$ Million) Table 36. Europe Migraine Therapeutics Market Size by Country (2023-2028) & (US$ Million) Table 37. Asia-Pacific Migraine Therapeutics Market Size by Region (2017-2022) & (US$ Million) Table 38. Asia-Pacific Migraine Therapeutics Market Size by Region (2023-2028) & (US$ Million) Table 39. Latin America Migraine Therapeutics Market Size by Country (2017-2022) & (US$ Million) Table 40. Latin America Migraine Therapeutics Market Size by Country (2023-2028) & (US$ Million) Table 41. Middle East & Africa Migraine Therapeutics Market Size by Country (2017-2022) & (US$ Million) Table 42. Middle East & Africa Migraine Therapeutics Market Size by Country (2023-2028) & (US$ Million) Table 43. Allergan Company Detail Table 44. Allergan Business Overview Table 45. Allergan Migraine Therapeutics Product Table 46. Allergan Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 47. Allergan Recent Development Table 48. Merck Company Detail Table 49. Merck Business Overview Table 50. Merck Migraine Therapeutics Product Table 51. Merck Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 52. Merck Recent Development Table 53. Pfizer Company Detail Table 54. Pfizer Business Overview Table 55. Pfizer Migraine Therapeutics Product Table 56. Pfizer Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 57. Pfizer Recent Development Table 58. Teva Company Detail Table 59. Teva Business Overview Table 60. Teva Migraine Therapeutics Product Table 61. Teva Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 62. Teva Recent Development Table 63. Amgen Company Detail Table 64. Amgen Business Overview Table 65. Amgen Migraine Therapeutics Product Table 66. Amgen Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 67. Amgen Recent Development Table 68. Johnson & Johnson Company Detail Table 69. Johnson & Johnson Business Overview Table 70. Johnson & Johnson Migraine Therapeutics Product Table 71. Johnson & Johnson Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 72. Johnson & Johnson Recent Development Table 73. Endo International Company Detail Table 74. Endo International Business Overview Table 75. Endo International Migraine Therapeutics Product Table 76. Endo International Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 77. Endo International Recent Development Table 78. GlaxoSmithKline Company Detail Table 79. GlaxoSmithKline Business Overview Table 80. GlaxoSmithKline Migraine Therapeutics Product Table 81. GlaxoSmithKline Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 82. GlaxoSmithKline Recent Development Table 83. Impax Company Detail Table 84. Impax Business Overview Table 85. Impax Migraine Therapeutics Product Table 86. Impax Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 87. Impax Recent Development Table 88. Abbott Company Detail Table 89. Abbott Business Overview Table 90. Abbott Migraine Therapeutics Product Table 91. Abbott Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 92. Abbott Recent Development Table 93. Bayer Company Detail Table 94. Bayer Business Overview Table 95. Bayer Migraine TherapeuticsProduct Table 96. Bayer Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 97. Bayer Recent Development Table 98. Eli Lilly Company Detail Table 99. Eli Lilly Business Overview Table 100. Eli Lilly Migraine TherapeuticsProduct Table 101. Eli Lilly Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 102. Eli Lilly Recent Development Table 103. Novartis International Company Detail Table 104. Novartis International Business Overview Table 105. Novartis International Migraine TherapeuticsProduct Table 106. Novartis International Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 107. Novartis International Recent Development Table 108. Ethypharm Company Detail Table 109. Ethypharm Business Overview Table 110. Ethypharm Migraine TherapeuticsProduct Table 111. Ethypharm Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 112. Ethypharm Recent Development Table 113. Kowa Pharmaceuticals America Company Detail Table 114. Kowa Pharmaceuticals America Business Overview Table 115. Kowa Pharmaceuticals America Migraine TherapeuticsProduct Table 116. Kowa Pharmaceuticals America Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 117. Kowa Pharmaceuticals America Recent Development Table 118. Winston Pharmaceuticals Company Detail Table 119. Winston Pharmaceuticals Business Overview Table 120. Winston Pharmaceuticals Migraine TherapeuticsProduct Table 121. Winston Pharmaceuticals Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 122. Winston Pharmaceuticals Recent Development Table 123. AstraZeneca Company Detail Table 124. AstraZeneca Business Overview Table 125. AstraZeneca Migraine TherapeuticsProduct Table 126. AstraZeneca Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 127. AstraZeneca Recent Development Table 128. Amirall Company Detail Table 129. Amirall Business Overview Table 130. Amirall Migraine TherapeuticsProduct Table 131. Amirall Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 132. Amirall Recent Development Table 133. OptiNose Company Detail Table 134. OptiNose Business Overview Table 135. OptiNose Migraine TherapeuticsProduct Table 136. OptiNose Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 137. OptiNose Recent Development Table 138. Revance Therapeutics Company Detail Table 139. Revance Therapeutics Business Overview Table 140. Revance Therapeutics Migraine TherapeuticsProduct Table 141. Revance Therapeutics Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 142. Revance Therapeutics Recent Development Table 143. RedHill Biopharma Company Detail Table 144. RedHill Biopharma Business Overview Table 145. RedHill Biopharma Migraine TherapeuticsProduct Table 146. RedHill Biopharma Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 147. RedHill Biopharma Recent Development Table 148. Bausch Health Company Detail Table 149. Bausch Health Business Overview Table 150. Bausch Health Migraine TherapeuticsProduct Table 151. Bausch Health Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 152. Bausch Health Recent Development Table 153. NeurAxon Company Detail Table 154. NeurAxon Business Overview Table 155. NeurAxon Migraine TherapeuticsProduct Table 156. NeurAxon Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 157. NeurAxon Recent Development Table 158. Biohaven Pharma Company Detail Table 159. Biohaven Pharma Business Overview Table 160. Biohaven Pharma Migraine TherapeuticsProduct Table 161. Biohaven Pharma Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 162. Biohaven Pharma Recent Development Table 163. Eisai Company Detail Table 164. Eisai Business Overview Table 165. Eisai Migraine TherapeuticsProduct Table 166. Eisai Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 167. Eisai Recent Development Table 168. Valeant Pharma Company Detail Table 169. Valeant Pharma Business Overview Table 170. Valeant Pharma Migraine TherapeuticsProduct Table 171. Valeant Pharma Revenue in Migraine Therapeutics Business (2017-2022) & (US$ Million) Table 172. Valeant Pharma Recent Development Table 173. Research Programs/Design for This Report Table 174. Key Data Information from Secondary Sources Table 175. Key Data Information from Primary Sources List of Figures Figure 1. Global Migraine Therapeutics Market Share by Type: 2021 VS 2028 Figure 2. Specific Anti-migraine Drugs Features Figure 3. Acute Therapies Features Figure 4. Preventative Therapies Features Figure 5. Other Features Figure 6. Global Migraine Therapeutics Market Share by Application in 2021 & 2028 Figure 7. Hospitals Case Studies Figure 8. Clinics Case Studies Figure 9. Household Use Case Studies Figure 10. Others Case Studies Figure 11. Migraine Therapeutics Report Years Considered Figure 12. Global Migraine Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 13. Global Migraine Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 14. Global Migraine Therapeutics Market Share by Region: 2021 VS 2028 Figure 15. Global Migraine Therapeutics Market Share by Players in 2021 Figure 16. Global Top Migraine Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Migraine Therapeutics as of 2021) Figure 17. The Top 10 and 5 Players Market Share by Migraine Therapeutics Revenue in 2021 Figure 18. North America Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 19. North America Migraine Therapeutics Market Share by Country (2017-2028) Figure 20. United States Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 21. Canada Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 22. Europe Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 23. Europe Migraine Therapeutics Market Share by Country (2017-2028) Figure 24. Germany Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 25. France Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 26. U.K. Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. Italy Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. Russia Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. Nordic Countries Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Asia-Pacific Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. Asia-Pacific Migraine Therapeutics Market Share by Region (2017-2028) Figure 32. China Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. Japan Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 34. South Korea Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 35. Southeast Asia Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 36. India Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 37. Australia Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. Latin America Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. Latin America Migraine Therapeutics Market Share by Country (2017-2028) Figure 40. Mexico Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. Brazil Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 42. Middle East & Africa Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 43. Middle East & Africa Migraine Therapeutics Market Share by Country (2017-2028) Figure 44. Turkey Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 45. Saudi Arabia Migraine Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 46. Allergan Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 47. Merck Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 48. Pfizer Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 49. Teva Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 50. Amgen Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 51. Johnson & Johnson Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 52. Endo International Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 53. GlaxoSmithKline Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 54. Impax Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 55. Abbott Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 56. Bayer Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 57. Eli Lilly Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 58. Novartis International Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 59. Ethypharm Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 60. Kowa Pharmaceuticals America Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 61. Winston Pharmaceuticals Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 62. AstraZeneca Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 63. Amirall Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 64. OptiNose Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 65. Revance Therapeutics Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 66. RedHill Biopharma Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 67. Bausch Health Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 68. NeurAxon Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 69. Biohaven Pharma Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 70. Eisai Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 71. Valeant Pharma Revenue Growth Rate in Migraine Therapeutics Business (2017-2022) Figure 72. Bottom-up and Top-down Approaches for This Report Figure 73. Data Triangulation Figure 74. Key Executives Interviewed

Allergan Merck Pfizer Teva Amgen Johnson & Johnson Endo International GlaxoSmithKline Impax Abbott Bayer Eli Lilly Novartis International Ethypharm Kowa Pharmaceuticals America Winston Pharmaceuticals AstraZeneca Amirall OptiNose Revance Therapeutics RedHill Biopharma Bausch Health NeurAxon Biohaven Pharma Eisai Valeant Pharma